Two pub­lic biotechs seek to merge, fo­cus­ing on desmoid tu­mors. But Nas­daq is not guar­an­teed

Two biotechs are look­ing to merge ear­ly next year, and as ne­go­ti­a­tions are on­go­ing, in­vestors still need to sign off on the deal.

On­col­o­gy-fo­cused Ad­vax­is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER